Logo image of FBIO

FORTRESS BIOTECH INC (FBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FBIO - US34960Q3074 - Common Stock

2.93 USD
-0.01 (-0.34%)
Last: 12/12/2025, 8:00:01 PM
2.91 USD
-0.02 (-0.68%)
After Hours: 12/12/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, FBIO scores 2 out of 10 in our fundamental rating. FBIO was compared to 531 industry peers in the Biotechnology industry. FBIO has a bad profitability rating. Also its financial health evaluation is rather negative. FBIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FBIO has reported negative net income.
In the past year FBIO has reported a negative cash flow from operations.
FBIO had negative earnings in each of the past 5 years.
FBIO had a negative operating cash flow in each of the past 5 years.
FBIO Yearly Net Income VS EBIT VS OCF VS FCFFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

FBIO has a Return On Assets of -2.94%. This is amongst the best in the industry. FBIO outperforms 86.82% of its industry peers.
The Return On Equity of FBIO (-9.55%) is better than 87.95% of its industry peers.
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIO Yearly ROA, ROE, ROICFBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

Looking at the Gross Margin, with a value of 71.56%, FBIO belongs to the top of the industry, outperforming 82.30% of the companies in the same industry.
FBIO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for FBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIO Yearly Profit, Operating, Gross MarginsFBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FBIO has more shares outstanding
FBIO has more shares outstanding than it did 5 years ago.
FBIO has a worse debt/assets ratio than last year.
FBIO Yearly Shares OutstandingFBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIO Yearly Total Debt VS Total AssetsFBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -6.12, we must say that FBIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FBIO (-6.12) is worse than 66.29% of its industry peers.
A Debt/Equity ratio of 0.86 indicates that FBIO is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.86, FBIO is doing worse than 74.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -6.12
ROIC/WACCN/A
WACC10.22%
FBIO Yearly LT Debt VS Equity VS FCFFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

FBIO has a Current Ratio of 2.19. This indicates that FBIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.19, FBIO is doing worse than 75.14% of the companies in the same industry.
A Quick Ratio of 1.97 indicates that FBIO should not have too much problems paying its short term obligations.
The Quick ratio of FBIO (1.97) is worse than 75.52% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.97
FBIO Yearly Current Assets VS Current LiabilitesFBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

FBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.37%, which is quite impressive.
The Revenue has decreased by -0.32% in the past year.
FBIO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.50% yearly.
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%

3.2 Future

FBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.48% yearly.
Based on estimates for the next years, FBIO will show a very strong growth in Revenue. The Revenue will grow by 64.44% on average per year.
EPS Next Y80.35%
EPS Next 2Y22.89%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FBIO Yearly Revenue VS EstimatesFBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIO Yearly EPS VS EstimatesFBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBIO. In the last year negative earnings were reported.
Also next year FBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBIO Price Earnings VS Forward Price EarningsFBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIO Per share dataFBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.89%
EPS Next 3Y11.48%

More info and screens

0

5. Dividend

5.1 Amount

FBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTRESS BIOTECH INC

NASDAQ:FBIO (12/12/2025, 8:00:01 PM)

After market: 2.91 -0.02 (-0.68%)

2.93

-0.01 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-24 2026-03-24/amc
Inst Owners15.05%
Inst Owner Change-4.53%
Ins Owners14.3%
Ins Owner Change0.03%
Market Cap90.95M
Revenue(TTM)62.30M
Net Income(TTM)-5.34M
Analysts82.5
Price Target10.97 (274.4%)
Short Float %16.04%
Short Ratio4.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-12.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.76%
Min EPS beat(2)-36.17%
Max EPS beat(2)125.68%
EPS beat(4)3
Avg EPS beat(4)24.21%
Min EPS beat(4)-36.17%
Max EPS beat(4)125.68%
EPS beat(8)6
Avg EPS beat(8)23.87%
EPS beat(12)7
Avg EPS beat(12)18.85%
EPS beat(16)9
Avg EPS beat(16)-3.2%
Revenue beat(2)1
Avg Revenue beat(2)-3.53%
Min Revenue beat(2)-17.76%
Max Revenue beat(2)10.71%
Revenue beat(4)2
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-17.76%
Max Revenue beat(4)10.85%
Revenue beat(8)3
Avg Revenue beat(8)-5.02%
Revenue beat(12)5
Avg Revenue beat(12)3.82%
Revenue beat(16)6
Avg Revenue beat(16)-2.87%
PT rev (1m)2.38%
PT rev (3m)-2.27%
EPS NQ rev (1m)21.59%
EPS NQ rev (3m)-6.7%
EPS NY rev (1m)36.36%
EPS NY rev (3m)55%
Revenue NQ rev (1m)-3.54%
Revenue NQ rev (3m)-32.99%
Revenue NY rev (1m)-1.63%
Revenue NY rev (3m)-14.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.46
P/FCF N/A
P/OCF N/A
P/B 1.63
P/tB 3.34
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS2.01
BVpS1.8
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.56%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 1.97
Altman-Z -6.12
F-Score4
WACC10.22%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
EPS Next Y80.35%
EPS Next 2Y22.89%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
EBIT growth 1Y10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.89%
EBIT Next 3Y5.48%
EBIT Next 5YN/A
FCF growth 1Y42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.14%
OCF growth 3YN/A
OCF growth 5YN/A

FORTRESS BIOTECH INC / FBIO FAQ

What is the fundamental rating for FBIO stock?

ChartMill assigns a fundamental rating of 2 / 10 to FBIO.


What is the valuation status for FBIO stock?

ChartMill assigns a valuation rating of 0 / 10 to FORTRESS BIOTECH INC (FBIO). This can be considered as Overvalued.


Can you provide the profitability details for FORTRESS BIOTECH INC?

FORTRESS BIOTECH INC (FBIO) has a profitability rating of 2 / 10.


How sustainable is the dividend of FORTRESS BIOTECH INC (FBIO) stock?

The dividend rating of FORTRESS BIOTECH INC (FBIO) is 0 / 10 and the dividend payout ratio is -12.44%.